Cytomegalovirus (CMV) Resistance Profile: Maribavir, Letermovir, Ganciclovir, Foscarnet, Cidofovir

Synonyms

  • CMV RESISTANCE-5 ANTIVIRAL MEDS
  • CYTOMEGALOVIRUS (CMV) RESISTANCE-5 ANTIVIRAL ME
  • LAB11121

Cerner Name

CMV Resistance-5 Antiviral Meds

Clinical Info

The CMV Resistance measures: Maribavir, Letermovir, Ganciclovir, Foscarnet, Cidofovir
Human Cytomegalovirus (CMV) infections are a major cause of morbidity and mortality among immunocompromised patients. 

Specimen Sources

Blood, Arterial Blood, Capillary Blood, Central Line Blood, Venous

Specimen Types

Blood

Specimen Volume

Container

Lavender Top Tube

Collection Instructions

Container/Tube: Lavender (EDTA) Top Tube
Specimen: 2 mL plasma (0.2 mL min)
  Samples must be received within 6 days of collection unless frozen

Transport Instructions

Refrigerated

Specimen Stability

7 Days room Temperature
7 Days Refrigerated
60 Days Frozen

Methodology

PCR followed by genotypic sequencing

Days Performed

TAT: 3 - 5 Days
Patient outcomes depend on effective prophylaxis and treatment with antiviral therapies, including maribavir, letermovir, cidofovir, ganciclovir, valganciclovir and foscarnet. Additionally, letermovir is approved specifically for prophylactic use in
hematopoietic stem cell transplant (HSCT) patients. Proper patient management requires rapid detection of resistance.
Laboratory testing should be used to confirm the occurrence of drug resistance, as treatment modification based solely
on clinical suspicion may result in added toxicity and increased complexity in patient management.
The CMV Resistance: Maribavir, Letermovir, Ganciclovir, Foscarnet, Cidofovir sequencing assay is designed to detect identified mutations in the UL54, UL56 and UL97 genes of CMV. The use of genotypic sequencing offers a rapid turnaround time, a broad range of antiviral resistance information, and the ability to provide information concerning new drugs as they become available

Performing Laboratories

Eurofins-Viracor

CPT

87910 x 3

PDM

235701

Results
Component Name Base Name Common Name External Name
MARIBAVIR UL97 MARIBAV MARIBAVIR UL97 Maribavir UL97
GANCICLOVIR UL97 GANC97 GANCICLOVIR UL97 Ganciclovir UL97
GANCICLOVIR UL54 GANC54 GANCICLOVIR UL54 Ganciclovir UL54
CIDOFOVIR UL54 CIDOFOVIR CIDOFOVIR UL54 Cidofovir UL54
FOSCARNET UL54 FOSCARNET FOSCARNET UL54 Foscarnet UL54
LETERMOVIR UL56 LETERUL56 LETERMOVIR UL56 Letermovir UL56

Result Interpretation

Mutations in the UL54, UL56 and UL97 genes will be reported as

Resistant/None Detected. Interpretation of gene mutations and

association with antiviral resistance, including maribavir, ganciclovir,

foscarnet, and cidofovir and letermovir will be provided with the report

 

Specificity

CMV sequencing analysis provides information about selected

locations in three genes, UL54, UL56, and UL97 involved in CMV antiviral resistance.

Forms
edit
Workgroup: ID Sendouts
Procedure Master Number: LAB11121
Build Info Make Changes to Compendium Info Open an Epic Change Request